1-{4-[4-(4-氯苯氧基)苯甲基]-1,3-噻唑-2-基}哌嗪二盐酸 | 28003-86-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-{4-[4-(4-氯苯氧基)苯甲基]-1,3-噻唑-2-基}哌嗪二盐酸
• 中文别名: 赖氨酸乳清酸盐
• 英文名称: Lysine orotate
• 英文别名: (2S)-2,6-diaminohexanoic acid;2,4-dioxo-1H-pyrimidine-6-carboxylic acid
• CAS: 28003-86-3
• 化学式: C11H18N4O6
• 分子量: 302.28
• InChiKey: FVGJURXBWORGKL-JEDNCBNOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.71
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  185
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• Stabilized phyllosilicates and method for their production
  申请人：Corning Glass Works

  公开号：EP0306172A1

  公开（公告）日：1989-03-08

  Stabilized, delaminated phyllosilicates as disclosed, and a method of producing the same, wherein the phyllosilicate is heated in the presence of a reactive vapor phase, preferably a hydrogen-containing atmosphere. The delaminated phyllosilicate is less than 1000Å thick, and is stabilized against moisture pickup. The formation of either a layer of a transition metal, or an organic reactive site, on the phyllosilicate surface is also disclosed. Also disclosed is a delaminated phyllosilicate particle of less than 1000Å thickness and having a coating of metal on its surface, the metal being selected from the transition elements and groups 3a, 4a, 5a and 6a of the Periodic Table. A method of producing such particle is shown, by an ion exchange treatment coupled with a reactive vapor phase/thermal treatment. A ceramic-metal composite composed of such metal coated particles compressed in a solid body is also disclosed.

  所公开的稳定分层植硅体及其生产方法，其中植硅体在反应气相（最好是含氢气氛）存在下加热。分层的植硅体厚度小于 1000埃，并具有稳定的防潮性能。此外，还公开了在植硅体表面形成过渡金属层或有机活性位点层的方法。 此外，还公开了一种厚度小于 1000Å 的脱层植硅酸盐颗粒，其表面有一层金属涂层，金属选自过渡元素和元素周期表中的 3a、4a、5a 和 6a 族。图中展示了通过离子交换处理和反应气相/热处理生产这种颗粒的方法。此外，还公开了一种陶瓷-金属复合材料，由压缩在固体中的这种金属涂层颗粒组成。
• Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases
  申请人：Health Now, Inc.

  公开号：EP0891771A1

  公开（公告）日：1999-01-20

  A therapeutic lysine-based composition and methods for its use in the prevention and treatment of cardiovascular disease is disclosed. The composition includes at least one lysine compound. The composition may also preferentially include ascorbate, proline and vitamin D or compounds thereof. The composition may also include N-acetyglucosamine and other compounds restoring and maintaining optimum biological function of the vascular wall. A patient at risk of developing or with a pre-existing cardiovascular disease is treated by administering orally or parenterally a desired dosage of the composition on a daily basis.

  本发明公开了一种基于赖氨酸的治疗性组合物及其用于预防和治疗心血管疾病的方法。该组合物包括至少一种赖氨酸化合物。该组合物还可优先包括抗坏血酸、脯氨酸和维生素 D 或其化合物。该组合物还可包括 N-乙酰葡萄糖胺和其他可恢复和维持血管壁最佳生物功能的化合物。通过每天口服或肠外给药所需剂量的组合物，对有可能患上或已经患上心血管疾病的患者进行治疗。
• Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis
  申请人：Wellstat Therapeutics Corporation

  公开号：EP1486210A1

  公开（公告）日：2004-12-15

  Pyrimidine nucleotide precursors including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.

  本研究公开了嘧啶核苷酸前体（包括胞苷、尿苷和乳清酸的酰基衍生物）和尿苷磷酸化酶抑制剂，以及它们在增强对败血症或全身性炎症的抵抗力方面的用途。
• Nutritional supplements including cardiovascular support components
  申请人：4Life Patents, LLC

  公开号：US10583168B1

  公开（公告）日：2020-03-10

  A composition for use in cardiovascular support includes transfer factor. The transfer factor may be nonmammalian transfer factor, such as that derived from eggs, or mammalian transfer factor, such as that derived from colostrum. The composition may also include one or more of the following: an LDL receptor-binding element; a blood flow-enhancing element; a cholesterol reducing element; a fat oxidation prevention element, and an antioxidant. Treatment methods include enlisting the immune system of a subject receiving therapy to attack pathogens that cause inflammation of blood vessels or to otherwise reduce inflammation of blood vessels.

  一种用于心血管支持的组合物包括转移因子。转移因子可以是非哺乳动物转移因子，如从鸡蛋中提取的转移因子，也可以是哺乳动物转移因子，如从牛初乳中提取的转移因子。组合物还可包括以下一种或多种：低密度脂蛋白受体结合元素；血流增强元素；降低胆固醇元素；防止脂肪氧化元素和抗氧化剂。治疗方法包括利用接受治疗者的免疫系统来攻击引起血管炎症的病原体，或以其他方式减轻血管炎症。
• Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
  申请人：——

  公开号：US20020094996A1

  公开（公告）日：2002-07-18

  The present invention provides compositions and methods for lowering plasma Lp(a) levels in humans. The present invention provides compositions and methods for lowering the risk factors for cardiovascular diseases. Moreover, this invention provides therapeutic alternatives to current pharmaceutical interventions for the lowering of cholesterol, LDL-cholesterol, triglycerides and other metabolic risk factors.

  本发明提供了降低人体血浆脂蛋白（a）水平的组合物和方法。本发明提供了降低心血管疾病风险因素的组合物和方法。此外，本发明还提供了目前降低胆固醇、低密度脂蛋白胆固醇、甘油三酯和其他代谢风险因素的药物干预的治疗替代方法。